Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.
Stereotactic ablative radiotherapy (SABR) has emerged as a highly promising treatment for medically inoperable early-stage non-small cell lung cancer patients. Treatment outcomes after SABR have been excellent compared to conventional fractionated radiotherapy (CFRT). However, the biological determinants of the response to ablative doses of radiation remain poorly characterized. Furthermore, there's little data on the cellular and molecular response of genetically distinct NSCLC subtypes to radiation. We assessed the response of 3 genetically distinct lung adenocarcinoma cell lines to ablative and fractionated ionizing radiation (AIR and FIR). We studied clonogenic survival, cell proliferation, migration, invasion, apoptosis and senescence. We also investigated the effect of AIR and FIR on the expression of pro-invasive proteins, epithelial-to-mesenchymal transition (EMT), extracellular signal-regulated kinases (ERK1/2) and the transmembrane receptor cMET. Our findings reveal that AIR significantly reduced cell proliferation and clonogenic survival compared to FIR in A549 cells only. This differential response was not observed in HCC827 or H1975 cells. AIR significantly enhanced the invasiveness of A549 cells, but not HCC827 or H1975 cells compared to FIR. Molecular analysis of pathways involved in cell proliferation and invasion revealed that AIR significantly reduced phosphorylation of ERK1/2 and upregulated cMET expression in A549 cells. Our results show a differential proliferative and invasive response to AIR that is dependent on genetic subtype and independent of intrinsic radioresistance. Further examination of these findings in a larger panel of NSCLC cell lines and in pre-clinical models is warranted for identification of biomarkers of tumor response to AIR.
a Department of Oncology , McGill University , Montreal , Quebec , Canada.
Ayman
A
Oweida
a Department of Oncology , McGill University , Montreal , Quebec , Canada.
Zeinab
Z
Sharifi
a Department of Oncology , McGill University , Montreal , Quebec , Canada.
Hani
H
Halabi
a Department of Oncology , McGill University , Montreal , Quebec , Canada.
Yaoxian
Y
Xu
a Department of Oncology , McGill University , Montreal , Quebec , Canada.
Siham
S
Sabri
a Department of Oncology , McGill University , Montreal , Quebec , Canada.
Bassam
B
Abdulkarim
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011839:Radiation, Ionizing; D016634:Radiosurgery / Q000379:methods*
Ablative radiotherapy; adenocarcinoma; cMET; invasion; lung cancer; proliferation